Glaxosmithkline Pharmaceutical share price
You have to be logged in to add this to Watchlist.- ₹3,231.05(-0.58%)July 11, 2025 12:06:03 PM IST
- NSE
- BSE
- Vol : 30.54K (NSE + BSE)Last 20 day avg : 124.51 K
Glaxosmithkline Pharmaceutical is trading -0.58% lower at Rs 3,231.05 as compared to its last closing price. Glaxosmithkline Pharmaceutical has been trading in the price range of 3,266.95 & 3,226.90. Glaxosmithkline Pharmaceutical has given 44.41% in this year & -1.52% in the last 5 days. Glaxosmithkline Pharmaceutical has TTM P/E ratio 52.84 as compared to the sector P/E of 22.90.There are 4 analysts who have initiated coverage on Glaxosmithkline Pharmaceutical. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 262.87 Crores in its last quarter.Listed peers of Glaxosmithkline Pharmaceutical include Abbott India (-0.47%), Alkem Laboratories (1.55%), Glaxosmithkline Pharmaceutical (-0.58%).The Mutual Fund holding in Glaxosmithkline Pharmaceutical was at 5.17% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Glaxosmithkline Pharmaceutical was at 4.52% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 11, 2025, 06:42 AM UTC
- Dividend YieldHigher than industry1.28Annual dividends as a percentage of the stock price.
- P/BHigher than historical values28.51The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values60.24Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.24Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 4.79% from Rs 974.37 crore to Rs 929.80 crore, year-on-year
- The company has grown its March quarter profit by 35.17% from Rs 194.48 crore to Rs 262.87 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 3,482.33
- R2
- 3,577.97
- R3
- 3,695.13
- S1
- 3,269.53
- S2
- 3,152.37
- S3
- 3,056.73
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Abbott India | Bullish | 34,450.00 | -0.47 | 73,390.04 | 53.21 | 17.78 | 1.34 | 3.73 |
| Alkem Laboratories | Bearish | 4,807.65 | 1.55 | 57,428.89 | 26.62 | 4.81 | 0.93 | 4.83 |
| Glaxosmithkline Pharmaceutical | Neutral | 3,231.05 | -0.58 | 54,716.87 | 60.53 | 28.67 | 1.27 | 0.13 |
| Glenmark Pharmaceuticals | Bullish | 2,145.70 | 12.63 | 60,455.39 | 37.95 | 5.69 | 0.14 | 7.90 |
| Biocon | Bullish | 373.20 | 0.21 | 49,835.42 | 47.70 | 2.08 | 0.13 | 59.81 |
- Promoter(s) holds a high stake in the company at 75.00%
- FIIs are invested in this company
- FIIs holding has increased by 0.02 percentage points from previous quarter
- Mutual Funds holding has increased by 0.21 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-08-01 | Quarterly Results |
| 2025-05-13 | Audited Results & Final Dividend |
| 2025-02-14 | Quarterly Results |
| 2025-02-10 | Quarterly Results |
| 2024-10-29 | Quarterly Results & Interim Dividend |
- IndustryBiotechnology & Drugs
- ISININE159A01016
- BSE Code500660
- NSE CodeGLAXO
Glaxosmithkline Pharmaceutical is trading at 3231.05 as on Fri Jul 11 2025 06:36:03. This is -0.58% lower as compared to its previous closing price of 3250.05.
The market capitalization of Glaxosmithkline Pharmaceutical is 54716.87 Cr as on Fri Jul 11 2025 06:36:03.
The 52 wk high for Glaxosmithkline Pharmaceutical is 3515.95 whereas the 52 wk low is 1924.30
Glaxosmithkline Pharmaceutical can be analyzed on the following key metrics -
- TTM P/E: 52.84
- Sector P/E: 22.90
- Dividend Yield: 1.29%
- D/E ratio: 0.01
Glaxosmithkline Pharmaceutical reported a net profit of 927.58 Cr in 2025.
The Mutual Fund Shareholding was 5.17% at the end of 31 Mar 2025.